News

HomeNews【Newsletter】October issue-Dress Pink Day | Voice Without Hoarseness: Transnasal Laryngoscopic Blue Laser Procedure for Efficient and Minimally Invasive Treatment of Vocal Cord Disorders | 40% Off Regular Breast Health Check-Up

【Newsletter】October issue-Dress Pink Day | Voice Without Hoarseness: Transnasal Laryngoscopic Blue Laser Procedure for Efficient and Minimally Invasive Treatment of Vocal Cord Disorders | 40% Off Regular Breast Health Check-Up

2025-10-02

“Chiron Newsletter” October issue: Click Here
This month's issue will bring you:

Dress Pink Day

With October being International Breast Cancer Awareness Month, support Dress Pink Day, focus on breast health, and stand with the power of pink! Individuals who pay for a 3D mammogram in October or women who visit on Dress Pink Day will receive a Pink Kit, which includes: Breast Self-examination Guide, Breast Cancer Info, Pink Ribbon Pin, and Exclusive Gifts from Sponsors.

Voice Without Hoarseness: Transnasal Laryngoscopic Blue Laser Procedure for Efficient and Minimally Invasive Treatment of Vocal Cord Disorders

Dr. LEE Shui-Kwong, Specialist in Otorhinolaryngology (ENT) from Chiron Medical, points out that if the vocal cords experience acute or chronic inflammation or lesions, it can lead to incomplete closure of the vocal cords, interfering with their vibration and resulting in a hoarse voice or even loss of voice. If hoarseness persists for two weeks, accompanied by difficulty swallowing, abnormal breathing sounds, painless lumps in the neck, or even blood in the sputum, immediate medical attention should be sought. For certain suitable cases, a newer minimally invasive procedure using transnasal laryngoscopic blue laser procedure, recently available in Hong Kong, may be employed to precisely address the affected tissue and help patients restore a clear voice.

40% Off Regular Breast Health Check-Up

The offer is valid until November 30, 2025. Appointments must be made, and the check-up completed by December 31, 2025. Reserve now! Early Check, Early Hope!